Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity
HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore…